{"schema_version":"secwatch.filing_event.v1","accession":"0001860782-24-000009","form_type":"8-K/A","ticker":null,"cik":"0001860782","company_name":"2seventy bio, Inc.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.122297+00:00","generated_at":"2026-06-06T10:11:00.705598+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"2seventy bio appoints William Baird as CEO and Victoria Eatwell as CFO effective at closing","bullets":["William D. Baird III appointed CEO; previously COO and CFO; base salary $575k, target bonus 55%.","Baird receives initial equity grant: option for 112,500 shares and RSUs for 56,250 shares.","Victoria Eatwell appointed CFO; previously SVP of Finance; base salary $425k, target bonus 40%.","Eatwell receives initial equity grant: option for 85,000 shares and RSUs for 42,500 shares.","Severance: Baird gets 1.5x base salary on change-in-control termination; Eatwell gets 1x base."],"urls":{"canonical":"https://secwatch.observer/filing/0001860782-24-000009","json":"https://secwatch.observer/filing/0001860782-24-000009.json","markdown":"https://secwatch.observer/filing/0001860782-24-000009.md","text":"https://secwatch.observer/filing/0001860782-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000009/0001860782-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000009/tvst-20240129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:11:00.705598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"077a54de77","claim":"Victoria Eatwell was appointed as Chief Financial Officer at 2seventy bio, Inc..","evidence_excerpt":"the Board appointed Victoria Eatwell as the chief financial officer of the Company, effective as of the date of the Closing.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000009/0001860782-24-000009-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"2a7e8b5338","claim":"William D. Baird, III was appointed as President and Chief Executive Officer at 2seventy bio, Inc..","evidence_excerpt":"the Board appointed William D. Baird, III as the president and chief executive officer of the Company, effective as of the date of the Closing.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000009/0001860782-24-000009-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}